Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
14 hedge funds and large institutions have $18.6M invested in Anebulo Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
17% more funds holding
Funds holding: 12 → 14 (+2)
2.45% more ownership
Funds ownership: 27.51% → 29.96% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less capital invested
Capital invested by funds: $21.6M → $18.6M (-$2.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.88M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
+$706K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$307K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$35.3K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$54 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.22M |
| 2 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
-$542K |
| 3 |
LA
LVW Advisors
Pittsford,
New York
|
-$68.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$27.6K |
| 5 |
BlackRock
New York
|
-$113 |
ANEB Hedge Fund Activity: Q4 2023 in Review
14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q4 2023, worth a combined $18.6M — down 14% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ANEB positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $1.88M. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.22M sold.
- 14 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $18.6M of Anebulo Pharmaceuticals stock for Q4 2023, down 14% quarter-over-quarter.
- 4 funds opened new Anebulo Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $1.88M added.
- The largest Anebulo Pharmaceuticals seller in Q4 2023 was Mangrove Partners, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2023.